glp-1 agonists ozempic Receptor Agonist Shortage: Challenges and Solutions in Type 2 Diabetes Care Is Semaglutide GLP-1 the Same

Burke, J

Lancet Neurol 14(3):329340 Biessels GJ, Verhagen C, Janssen J et al (2019) Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial

NanoPortalTM Platform Technology - Vivani [Internet]

Key Points Three companies to watch in the fast-growing GLP-1 space include firms with market capitalizations ranging from about $4 billion to nearly $1 trillion

[Crossref] [PubMed] Gelaye B, Sacco S, Brown WJ, et al

News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s